Literature DB >> 17492354

Massive infiltration of bone marrow in colon carcinoma after treatment with activated protein C.

Lisa Pleyer1, Philip Went, Gudrun Russ, Erika Prinz, Viktoria Faber, Hans-Joachim Röwert, Renate Karlbauer, Richard Greil.   

Abstract

We present an unusual case of localized colorectal carcinoma complicated by sepsis which was treated with activated protein C (APC). Shortly after treatment the patient developed symptomatic metastases to the bone marrow (BM). Destruction of bones by colorectal cancer (CRC) is rare, although BM micrometastases are frequently observed. However, overt symptomatic BM metastasis is an exotic rarity. APC interacts with molecules and modulates pathways that are unquestionably involved in tumorigenesis and formation of metastases. Therefore a possible contributory role of the anti-inflammatory and immunomodulatory therapy in the rapid evolution of the disease cannot be excluded. Questions concerning the relevance and contribution of sepsis, treatment with APC, exquisitely high levels of non-thrombosis-associated D-dimer and CA19-9 to this highly uncommon course of disease are discussed. The lesson learned from this case is that APC may have contributed to the massive invasion of BM by colonic cancer cells in our patient and that APC should therefore be used with extreme restraint in patients with potentially curable cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17492354     DOI: 10.1007/s00508-007-0774-7

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  20 in total

1.  Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line.

Authors:  B White; M Schmidt; C Murphy; W Livingstone; D O'Toole; M Lawler; L O'Neill; D Kelleher; H P Schwarz; O P Smith
Journal:  Br J Haematol       Date:  2000-07       Impact factor: 6.998

2.  Effect of inflammatory cytokines and growth factors on tumour cell adhesion to the peritoneum.

Authors:  M E van Rossen; L J Hofland; M P van den Tol; P M van Koetsveld; J Jeekel; R L Marquet; C H van Eijck
Journal:  J Pathol       Date:  2001-04       Impact factor: 7.996

3.  Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.

Authors:  J Abe; T Urano; H Konno; Y Erhan; T Tanaka; N Nishino; A Takada; S Nakamura
Journal:  Cancer       Date:  1999-12-15       Impact factor: 6.860

4.  Efficacy and safety of recombinant human activated protein C for severe sepsis.

Authors:  G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher
Journal:  N Engl J Med       Date:  2001-03-08       Impact factor: 91.245

5.  Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.

Authors:  H Allgayer; M M Heiss; R Riesenberg; K U Grützner; A Tarabichi; R Babic; F W Schildberg
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

6.  Preoperative plasma plasminogen activator inhibitor type-1 and serum C-reactive protein levels in patients with colorectal cancer. The RANX05 Colorectal Cancer Study Group.

Authors:  H J Nielsen; I J Christensen; S Sørensen; F Moesgaard; N Brünner
Journal:  Ann Surg Oncol       Date:  2000-09       Impact factor: 5.344

7.  Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.

Authors:  L Buø; G I Meling; T S Karlsrud; H T Johansen; A O Aasen
Journal:  Hum Pathol       Date:  1995-10       Impact factor: 3.466

8.  Role of activated protein C in facilitating basement membrane invasion by tumor cells.

Authors:  H Kobayashi; N Moniwa; J Gotoh; M Sugimura; T Terao
Journal:  Cancer Res       Date:  1994-01-01       Impact factor: 12.701

Review 9.  [Histopathology and tumor markers].

Authors:  Hiroshi Kijima; Yoshito Ueyama; Yoshiyuki Osamura
Journal:  Rinsho Byori       Date:  2003-12

10.  Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells.

Authors:  C Trân-Thang; E Kruithof; H Lahm; W A Schuster; M Tada; B Sordat
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

View more
  3 in total

1.  Favorable control of advanced colon adenocarcinoma with severe bone marrow metastasis: A case report.

Authors:  Fumiyasu Hanamura; Yoshihiro Shibata; Tsuyoshi Shirakawa; Miyuki Kuwayama; Hisanobu Oda; Hiroshi Ariyama; Kenichi Taguchi; Taito Esaki; Eishi Baba
Journal:  Mol Clin Oncol       Date:  2016-09-21

2.  The EGF 61A/G polymorphism - a predictive marker for recurrence of liver metastases from colorectal cancer.

Authors:  Florian M Kovar; Christiane Thallinger; Claudia L Marsik; Thomas Perkmann; Harald Puhalla; Helmuth Haslacher; Fritz Wrba; Oswald F Wagner; Thomas Gruenberger; Georg Endler
Journal:  Wien Klin Wochenschr       Date:  2009       Impact factor: 1.704

3.  Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement.

Authors:  Geerte L Van Sluis; Tatjana M H Niers; Charles T Esmon; Wikky Tigchelaar; Dick J Richel; Harry R Buller; Cornelis J F Van Noorden; C Arnold Spek
Journal:  Blood       Date:  2009-07-01       Impact factor: 22.113

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.